Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791709 | 0.89 | NAAA (0.58) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL12792217 | 0.89 | NAAA (0.58) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL12792190 | 0.89 | NAAA (0.58) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL12791923 | 0.89 | NAAA (0.58) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL12792093 | 0.89 | NAAA (0.58) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL652484 | 0.89 | NAAA (0.58) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL13755911 | 0.88 | PAOX (0.46) | PAOXDNM1NAAAKDM4EHSD17B10 | |
| SCHEMBL9290503 | 0.88 | NAAA (0.57) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL25607772 | 0.88 | NAAA (0.57) | PAOXDNM1NAAAFAAHCASP2 | |
| SCHEMBL889191 | 0.88 | DNM1 (0.49) | DNM1NAAAGAAFAAHCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | PAOX 1247/4885DNM1 4279/4885NAAA 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.